Erectile Dysfunction Clinical Trial
— HeezOn-UltraOfficial title:
A Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
Verified date | June 2016 |
Source | Vedic Lifesciences Pvt. Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Sexual function is a part of a normal healthy life and considered to be essential for
mental, physical and marital well-being. Any derangement in normal function though is a
distressing situation for the individual, is often not reported due to embarrassment or due
to social stigma. Sexual disorders in men are categorized according to the stage of sexual
response affected in terms of disorders of erectile function, ejaculatory function or
libido, albeit there is considerable potential for overlap amongst the disorders. The use of
current intervention has many side-effects and has been prohibited in cardiovascular
condition and also to be taken with caution with other medical condition.
This has led to the development of multiple alternate therapies which are helpful for a
limited number of cases but the major concern for all these therapies is their late onset of
action and not having a sustained effect.
Status | Completed |
Enrollment | 15 |
Est. completion date | January 2017 |
Est. primary completion date | January 2017 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: 1. Planning to have regular sexual activity (more than twice/ week). 2. Body Mass Index should be = 29 kg/m2. 3. Subjects suffering from erectile dysfunction indicated by SHIMscore = 12 and = 16 for more than 3 months and less than 6 months. OR 4. Subjects suffering from predominantly from premature ejaculation as indicated by PEDT score more than 11 for more than 3 months and less than 6 months. 5. Fasting blood sugar = 120 mg/dl. 6. The subjects have to be non-smoker and non-alcoholic. Exclusion Criteria: 1. Subjects having SHIM score <12 and > 16. 2. Subjects suffering from premature ejaculation predominantly as indicated by PEDT score less than 11. 3. Subjects with major psychiatric disorders or severe systemic disorders 4. Subject having uncontrolled diabetes mellitus and hypertensive on active treatment 5. Subjects having history of male sexual dysfunction more than six months in diabetic subjects. 6. Anatomical deformity of the penis such as severe penile fibrosis or Peyronie's disease or phimosis. 7. Subjects detected with HIV and suffering from AIDS. 8. Has an abnormal thyroid stimulating hormone (TSH) level lower than 30% of lower limit normal or more than 30% of upper limit normal. 9. Has erectile dysfunction caused by neurological or endocrine factors such as hyper-prolactinemia. 10. Subjects with history of major systemic disorders. 11. Subject with history of drug abuse. 12. Subjects using medications known to cause sexual dysfunction (cimetidine, spironolactone, thiazides, adrenergic blockers, antidepressants etc.) 13. Subject has participated in any clinical trial within last 30 days. 14. Subjects not ready to sign the consent & unable to comply the protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Vedic Lifesciences Pvt. Ltd. | Enovate Biolife Pvt Ltd |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in scores of Sexual Health Inventory for Men | Day 0, Day 1, Day 3, Day 14 and Day 28 | ||
Secondary | Sexual Hormone Binding Globulin | Day 0 and Day 14 | ||
Secondary | Free Testosterone | Day 0 and Day 14 | ||
Secondary | Change in scores of Sexual Quality of Life - Male | Day 0, Day 1, Day 3, Day 14 and Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |